TNFRSF8 and Hodgkins lymphoma: Iratumumab (MDX-060), a fully humanized IgG1κ mAb that also belongs to the first-generation agents targeting CD30, is a marker of Reed-Sternberg cells in Hodgkin lymphoma (HL) and of anaplastic large cell lymphoma (ALCL), while it is also expressed in various types of other lymphomas and in embryonal carcinoma.